<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Burn Care Res</journal-id><journal-id journal-id-type="iso-abbrev">J Burn Care Res</journal-id><journal-id journal-id-type="pmc-domain-id">3467</journal-id><journal-id journal-id-type="pmc-domain">jbcr</journal-id><journal-id journal-id-type="publisher-id">jbcr</journal-id><journal-title-group><journal-title>Journal of Burn Care &amp; Research: Official Publication of the American Burn Association</journal-title></journal-title-group><issn pub-type="ppub">1559-047X</issn><issn pub-type="epub">1559-0488</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10152994</article-id><article-id pub-id-type="pmcid-ver">PMC10152994.1</article-id><article-id pub-id-type="pmcaid">10152994</article-id><article-id pub-id-type="pmcaiid">10152994</article-id><article-id pub-id-type="pmid">36638083</article-id><article-id pub-id-type="doi">10.1093/jbcr/irad004</article-id><article-id pub-id-type="publisher-id">irad004</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Summary Articles</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00910</subject></subj-group></article-categories><title-group><article-title>State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1119-1901</contrib-id><name name-style="western"><surname>Hill</surname><given-names initials="DM">David M</given-names></name><degrees>Pharm.D, BCPS, BCCCP, FCCM</degrees><aff>
<institution>Clinical Pharmacist, Department of Pharmacy, Regional One Health</institution>, <addr-line>877 Jefferson Avenue, Memphis, Tennessee 38103</addr-line>, <country country="US">USA</country></aff><xref rid="c1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>DeBoer</surname><given-names initials="E">Erik</given-names></name><degrees>PhD</degrees><aff>
<institution>Trevena, Inc.</institution>, <country country="US">USA</country></aff></contrib></contrib-group><author-notes><corresp id="c1">Address correspondence to David M. Hill, Pharm.D, BCPS, BCCCP, FCCM, Associate Professor, Department of Clinical Pharmacy &amp; Translational Science, College of Pharmacy, University of Tennessee Health Science Center, USA. Email: <email>dmhill@regionalonehealth.org</email></corresp></author-notes><pub-date pub-type="collection"><season>May-Jun</season><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-01-13"><day>13</day><month>1</month><year>2023</year></pub-date><volume>44</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">434784</issue-id><fpage>524</fpage><lpage>534</lpage><history><date date-type="corrected-typeset"><day>15</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>03</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-03 10:25:12.343"><day>03</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023. Published by Oxford University Press on behalf of the American Burn Association.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="irad004.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="irad004.pdf"/><abstract><title>Abstract</title><p>Pain associated with severe burn injury is one of the most intense and clinically challenging to manage, as the metabolic imbalances associated with the inflammation caused by the injury and treatment interventions (e.g., dressing changes and debridement, excision, and grafting) can further worsen the pain. In the pharmacologic management of a complex, hospitalized patient with burn injuries, opioid therapy remains an efficacious mainstay of treatment. However, the complex nature of pain, injury characteristics, and common demographics after burn injury place patients at high risk of opioid-related adverse events. Thus, guidelines recommend that decisions about choice of opioid be based on physiology, pharmacology, and physician experience, in addition to individualizing initial treatment with subsequent continual adjustments throughout care. Although substantial progress has been made in pain management strategies with utilization of nonopioid medications and nonpharmacologic adjuncts to opioid pharmacotherapy, there is still a need to evaluate new therapies, as an optimal regimen still lacks significant evidential support. Herein, we review the actions of opioids at the cellular level, contributing to both nociception and opioid-related adverse events. We also discuss the most recently approved intravenously administered opioid, oliceridine, developed utilizing biased ligand technology, including a summary of its clinical efficacy and safety in the management of severe acute pain. While oliceridine has been evaluated for the management of moderate-to-severe acute pain, the large phase 3 studies did not include patients with burn injuries. However, potential implications and future study direction for pain associated with burn injury are discussed.</p></abstract><kwd-group><kwd>Burns</kwd><kwd>Analgesics</kwd><kwd>Opioid</kwd><kwd>Pain</kwd><kwd>Adverse Drug Event</kwd></kwd-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Pain caused by acute, severe burn injury is one of the most intense and clinically challenging to manage, as the metabolic imbalances associated with the inflammation caused by the injury and treatment interventions (eg, dressing changes and debridement, excision, and grafting) can further worsen the pain. Part of the challenge is the involved complexity. After acute burn injury, both injured tissue and adjacent nonburned tissue upregulate response to painful and non-painful stimuli (hyperalgesia and allodynia, respectively).<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways.<sup><xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0003" ref-type="bibr">3</xref></sup> Throughout the patient&#8217;s course of treatment, this has been described in several categories: Background pain that occurs from the burn injury itself while the patient is otherwise at rest, breakthrough pain (ie, a transient exacerbation of pain), and evoked or procedural pain (ie, associated with wound manipulation such as routine debridement and dressing changes). As such, each patient&#8217;s trajectory is unique, necessitating customized management while caring for patients with acute burn pain. In addition to the primary injury, severe burns also may require use of autografts to facilitate appropriate healing and function, complicating and intensifying the patient&#8217;s discomfort, given donor sites are often more painful than the burned tissue because underlying dermal nociceptors are often largely intact and nerves newly exposed after harvesting.<sup><xref rid="CIT0004" ref-type="bibr">4</xref></sup></p><p>Over the past several years, the burn community has employed increasingly sophisticated methods to enhance pain control through pharmacologic and nonpharmacologic means. Such methods have included distraction,<sup><xref rid="CIT0005" ref-type="bibr">5</xref></sup> music therapy,<sup><xref rid="CIT0006" ref-type="bibr">6</xref></sup> aromatherapy,<sup><xref rid="CIT0007" ref-type="bibr">7</xref>,<xref rid="CIT0008" ref-type="bibr">8</xref></sup> acupuncture,<sup><xref rid="CIT0009" ref-type="bibr">9</xref></sup> oral and intravenous (IV) ketamine, and bupivacaine.<sup><xref rid="CIT0010" ref-type="bibr">10&#8211;13</xref></sup> The goal of this work has been to expand the multimodal armamentarium and to manage acute pain while minimizing the known, long-term negative consequences of poorly managed pain such as post-traumatic stress disorder and the development of chronic pain.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0015" ref-type="bibr">15</xref></sup> The truth is that there are few options known to date to completely control all the involved aspects of acute burn pain and offer relief to the affected patients.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> While the field continues to make substantial progress in evolving nonopioid pain therapies, opioid therapy remains an efficacious and necessary component in the pharmacologic management of a hospitalized burn patient.<sup><xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0016" ref-type="bibr">16&#8211;18</xref></sup> Opioids carry their own risks, including dependence, tolerance, and hyperalgesia in addition to inherent side effects,<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> and a benefit-risk assessment needs to be made for the patient while considering opioid class effects including risks of respiratory depression, addiction, abuse, and misuse. Advances in the treatment of pain with the use of opioids; however, have been limited, presenting opportunities for additional investigation.</p><p>Recently published guidelines recommend that decisions about the choice of narcotic be based on the physiology, pharmacology, and prescriber&#8217;s experience. Furthermore, the guidelines also recommend <italic toggle="yes">&#8220;opioid therapy should be individualized to each patient and continuously adjusted throughout their care due to the heterogeneity of individual responses, adverse effects, and the narrow therapeutic window of opioids (Level D)</italic>&#8221;.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> In practice, the profound physiological changes accompanying major burn injury, including hypovolemia, edema, and hypoalbuminemia during the first 48 hours, followed by a hyperdynamic state with high blood flow in the kidneys and liver beyond 48 hours, contribute to altered pharmacokinetic and pharmacodynamic responses to many drugs,<sup><xref rid="CIT0019" ref-type="bibr">19</xref></sup> including opioids,<sup><xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0020" ref-type="bibr">20</xref></sup> and burn patients often require higher-than-recommended doses of opioid analgesics for adequate pain relief.<sup><xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0021" ref-type="bibr">21</xref></sup> High requirements, combined with lingering active metabolites and dangerous drug&#8211;drug interactions, place patients with burn injuries at a higher risk of developing opioid-related adverse events (ORAEs) such as nausea, vomiting, respiratory depression, constipation, sedation, and pruritus. This concern is further heightened for patients at the extremes of ages or frail, have high body mass index (BMI) or are obese, or have pre-existing comorbidities.<sup><xref rid="CIT0022" ref-type="bibr">22&#8211;25</xref></sup> Post-operative patients experiencing a single ORAE require 47% higher healthcare utilization, including resources, costs, and length of stay.<sup><xref rid="CIT0026" ref-type="bibr">26</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref></sup></p><p>Burn patients are often treated with opioids for several days or even weeks depending on the severity and extent of their injuries which may present additional therapeutic challenges. Both injured tissue and adjacent non-burned tissue upregulate responses to painful and non-painful stimulus over time and generate hyperalgesia or allodynia.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref></sup> Moreover, pruritus is very common during the wound healing process after a burn, with a reported prevalence of 80%&#8211;100% that worsens healing, further complicating the recovery process and lowering the quality of life.<sup><xref rid="CIT0030" ref-type="bibr">30</xref></sup></p><p>An additional consideration for burn patients treated with opioids for extended periods is the development of tolerance, wherein the dose&#8211;response of a given opioid therapy will decrease over time, effectively elevating the dose requirements to achieve a similar analgesic benefit.<sup><xref rid="CIT0021" ref-type="bibr">21</xref></sup> Apart from the cost consequences of additional therapy, analgesia and ORAEs may not exhibit tolerance at the same rate, leaving patients proportionally more prone to adverse effects (AEs) as tolerance develops.<sup><xref rid="CIT0031" ref-type="bibr">31</xref></sup> Tolerance is often addressed clinically by using an opioid which potentiates a slightly different portion of the mu opioid receptor (mOR) pathway.<sup><xref rid="CIT0032" ref-type="bibr">32</xref></sup> Other strategies include using low doses of naloxone or buprenorphine to aid in receptor availability<sup><xref rid="CIT0033" ref-type="bibr">33</xref>,<xref rid="CIT0034" ref-type="bibr">34</xref></sup>; however, these options add unpredictability and further complicate pain control and ORAE management.<sup><xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0035" ref-type="bibr">35</xref></sup></p><p>Tolerance develops in part due to the activity of intracellular effectors downstream of the mOR. mORs are G-protein-coupled receptors (GPCRs), where G-protein activation results in inhibition of adenylyl cyclase and activation of phospholipase C. This serves to carry out the analgesic cascade of &#181; agonism by reduction of cyclic adenosine monophosphate and release of substance P as well as the inhibition of voltage-dependent Ca2+ channels and activation of inwardly rectifying K+ channels (<xref rid="F1" ref-type="fig">Figure 1</xref>).<sup><xref rid="CIT0036" ref-type="bibr">36</xref></sup> After repeated signaling, a group of GPCR kinases known as the &#8220;arrestin&#8221; family, phosphorylate the mOR, blunting additional G-protein-coupled analgesic signaling through an internal feedback loop.<sup><xref rid="CIT0037" ref-type="bibr">37</xref></sup> Over time, receptor internalization or endocytosis occurs, reducing the presence of mOR at the post-synaptic surface through a beta arrestin-mediated mechanism.<sup><xref rid="CIT0038" ref-type="bibr">38</xref></sup> In this way, with repeated signaling of the mOR, it becomes less effective (desensitization) over time due to agonism of the endogenous arrestin pathway.<sup><xref rid="CIT0039" ref-type="bibr">39</xref></sup> When fewer mORs are present at the post-synaptic terminal the ability of a &#181; agonist to elicit its analgesic effects is proportionally lower, effectually desensitizing the system to &#181; agonism.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><p>
<bold>Schematic depiction of pain transduction (<italic toggle="yes">left panel</italic>) and analgesic mechanism of action of opioids on the pain pathway (<italic toggle="yes">right panel</italic>).</bold> (<italic toggle="yes">Left panel</italic>) Pain pathway: Following activation of nociceptors, <bold>1)</bold> signal transduction in pre-synaptic neurons results in activation of adenylyl cyclase and cyclic adenosine monophosphate (cAMP)-mediated release of neurotransmitters (glutamate, substance P, calcitonin gene-related protein [CGRP]) into the synaptic cleft; <bold>2)</bold> released neurotransmitters bind to specific post-synaptic receptors: glutamate to the &#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors, substance P to the neurokinin-1 (NK-1) receptor, and CGRPs to the CGRP receptors (CGRP-R); <bold>3)</bold> Activation of AMCP and NMDA receptors leads to an increase in the flow of positively-charged ions such as Ca2+ and Na2+ and increase in pain signal; another positive ion, Mg2+, is mobilized following NK-1 receptor binding-mediated protein kinase C activation and acts indirectly by unblocking NMDA receptors; <bold>4)</bold> Substance P also mediates an increase in the influx of Ca2+ into the presynaptic neuron, contributing to increased neurotransmitter release and signaling; <bold>5)</bold> Although the mechanism is not completely clear, activation of CGRP-R(s) is also believed to contribute to neuromodulation in the periphery similar to its involvement in migraine headache pathophysiology. (<italic toggle="yes">Right panel</italic>) Opioid Analgesic Action: Four subtypes of opioid receptors are present on both pre- and post-synaptic neurons: mu (&#181;) opioid receptor (mOR), kappa (&#954;) opioid receptor (kOR), delta (&#948;) opioid receptor (dOR), and nociception-related G protein-coupled receptor (<italic toggle="yes">non-naloxone-binding; not shown in figure</italic>). <bold>1)</bold> Both endogenous and exogenous opioids bind to the mOR, resulting in a series of actions that inhibit pain signaling; <bold>2)</bold> Activation of mOR results in an inhibition of adenylyl cyclase, leading to an inhibition of cAMP release and subsequent inhibition of neurotransmitters; <bold>3)</bold> mOR binding also inhibits voltage-gated Ca2* channels and influx of positive ions into the pre-synaptic neuron, contributing to an inhibition of neurotransmitter release; <bold>4)</bold> Finally, binding of opioids to the mOR on the post-synaptic neuron results in an opening of G protein-gated K+ channels, facilitating efflux of K+ ions and hyperpolarization leading to decreased sensitization to pain signaling.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="irad004_fig1.jpg"/></fig><p>Few animal burn pain models have demonstrated differential opioid efficacy. Existing guidelines are supported with low quality studies and graded levels of evidence.<sup><xref rid="CIT0022" ref-type="bibr">22</xref></sup> However, evaluating drug-specific differences in a clinical setting of acute burn pain is difficult.<sup><xref rid="CIT0018" ref-type="bibr">18</xref></sup> As such, findings from other pain models are extrapolated to this setting. This review highlights an historical account of opioid use and turns attention to a next generation of &#181;-opioid agonist, oliceridine, and its potential to aid patients and providers caring for patients with burn injuries.</p></sec><sec id="s2"><title>Opioids: Historical Compounds</title><p>Opioids (refers to opiates, the natural products obtained from the opium poppy, as well as semi-synthetic or synthetic opioids) are ubiquitous in the management of pain.<sup><xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0040" ref-type="bibr">40</xref></sup> Morphine was the first opium available in the early 1800s, followed by codeine (which although found in opium, can also be synthesized). Their widespread use led to the original Pure Food and Drug Act of 1906&#8212;the first piece of U.S. federal legislation regulating the pharmaceutical marketplace.<sup><xref rid="CIT0041" ref-type="bibr">41</xref></sup> The first synthetic opioid medications were developed in the 1910s, with the availability of methadone in 1947<sup><xref rid="CIT0042" ref-type="bibr">42</xref></sup> and oxymorphone in 1959. In the 1960s and 1970s, the US Food and Drug Administration (FDA) approved short-acting agents such as fentanyl and combination products such as oxycodone/acetaminophen (1976). In the late 1980s and early 1990s, the FDA approved additional semi-synthetic opioids (eg, hydromorphone, hydrocodone, oxycodone, tramadol), combination products, and long-acting formulations, such as morphine sulfate controlled-release (MS Contin<sup>&#174;</sup> in 1985) and oxycodone extended-release (ER) (1995). Starting around 2008-2011, the FDA has approved a cohort of opioids, including tapentadol and other ER compounds with abuse-deterrent properties (tapentadol ER, hydromorphone ER) (<xref rid="F2" ref-type="fig">Figure 2</xref>).<sup><xref rid="CIT0041" ref-type="bibr">41</xref></sup> Oliceridine was approved in 2020 for the management of acute pain severe enough to require an IV opioid analgesic and for whom alternative treatments are inadequate.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2:</label><caption><p>Timeline of Availability of Opioids.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="irad004_fig2.jpg"/></fig><sec id="s3"><title>Actions of Opioids at the Cellular Level</title><p>Exogenous opioids mimic and potentiate the physiologic action of endogenous opioids, through their activity on opioid receptors.<sup><xref rid="CIT0036" ref-type="bibr">36</xref></sup> The opioid system consists of four receptor subtypes, including, mu (&#181;), kappa (&#954;), delta (&#948;), and nociception that are GPCRs sharing the similar seven-transmembrane topology. The nociception-opioid receptor (nOR) subtype does not bind naloxone, nor are its effects reversed by naloxone, and is considered a non-classical opioid receptor. Classical opioid receptors are expressed widely within the central nervous system and, to a lesser extent, throughout the periphery tissues (including skin, joints, viscera).<sup><xref rid="CIT0043" ref-type="bibr">43</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref></sup> The analgesic effects of opioids are elicited by central activation of opioid receptors; however, many of the AEs (eg, gastrointestinal (GI) motility, urinary retention, and pruritus) are regulated by activation of peripherally located opioid receptors.<sup><xref rid="CIT0045" ref-type="bibr">45</xref></sup></p></sec><sec id="s4"><title>Opioid Effects by Receptor Subtype</title><p>In addition to contributing predominantly to the analgesic effect, mORs are responsible for respiratory depression, euphoria, sedation, reduced GI motility, and physical dependence.<sup><xref rid="CIT0046" ref-type="bibr">46</xref></sup> Activation of the &#954; opioid receptors (kORs) can cause sedation, dyspnea, dependence, dysphoria, respiratory depression, and spinal analgesia,<sup><xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0046" ref-type="bibr">46</xref></sup> while &#948; opioid receptor (dOR) activity modulates rewarding activities of a number of drugs of abuse, and influences several aspects of addictive behaviors including drug-seeking, emotional responses, and learning processes.<sup><xref rid="CIT0043" ref-type="bibr">43</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref></sup> dORs co-localize with mORs in enteric neurons, and also contribute to reduced GI motility.<sup><xref rid="CIT0048" ref-type="bibr">48</xref></sup> Data from animal studies show that mOR and dOR activation causes respiratory depression as a result of decreased breathing frequency, and kOR activation causes an increase in tidal volume.<sup><xref rid="CIT0049" ref-type="bibr">49</xref></sup> The most common effects by opioid receptor subtypes are shown in <xref rid="T1" ref-type="table">Table 1</xref>. An image to be recounted later, it is important to conceptualize that opioids can be selective to a particular receptor, but still have activity at other GPCRs. For example, morphine has a higher affinity for mOR of the GPCR, but also retains differing levels of binding capacity to kOR and dOR.<sup><xref rid="CIT0050" ref-type="bibr">50&#8211;52</xref></sup> All opioids are not necessarily created equally.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1:</label><caption><p>Most common effects of opioids based on activation of receptor subtypes</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Mu (mOR)</th><th align="center" rowspan="1" colspan="1">Kappa (kOR)</th><th align="center" rowspan="1" colspan="1">Delta (dOR)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Analgesia</td><td align="center" rowspan="1" colspan="1">Analgesia</td><td align="center" rowspan="1" colspan="1">Analgesia</td></tr><tr><td align="center" rowspan="1" colspan="1">Respiratory depression</td><td align="center" rowspan="1" colspan="1">Respiratory depression</td><td align="center" rowspan="1" colspan="1">Respiratory depression</td></tr><tr><td align="center" rowspan="1" colspan="1">Sedation</td><td align="center" rowspan="1" colspan="1">Sedation</td><td align="center" rowspan="1" colspan="1">Affective behavior</td></tr><tr><td align="center" rowspan="1" colspan="1">Miosis</td><td align="center" rowspan="1" colspan="1">Miosis</td><td align="center" rowspan="1" colspan="1">Reinforcing actions</td></tr><tr><td align="center" rowspan="1" colspan="1">Euphoria</td><td align="center" rowspan="1" colspan="1">Dysphoria</td><td align="center" rowspan="1" colspan="1">Reduced GI motility</td></tr><tr><td align="center" rowspan="1" colspan="1">Reduced GI motility</td><td align="center" rowspan="1" colspan="1">Hallucinations</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Physical dependence</td><td align="center" rowspan="1" colspan="1">Physical dependence</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T1Fn1"><p>Note: <italic toggle="yes">dOR</italic>, delta opioid receptor; <italic toggle="yes">GI</italic>, gastrointestinal; <italic toggle="yes">kOR</italic>, kappa opioid receptor; <italic toggle="yes">mOR</italic>, mu opioid receptor.</p></fn></table-wrap-foot></table-wrap><p>Although, one or more receptor subtypes can be involved with analgesic effects and AEs, multiple mechanisms could mediate differential <italic toggle="yes">in vivo</italic> activities of drugs targeting opioid receptors.<sup><xref rid="CIT0053" ref-type="bibr">53</xref></sup> Indeed, factors such as intrinsic drug efficacy, pharmacogenetics,<sup><xref rid="CIT0054" ref-type="bibr">54&#8211;56</xref></sup> pharmacodynamics, drug selectivity, and accessibility to selective receptor populations may contribute to differential effects of many opioid agonists.<sup><xref rid="CIT0053" ref-type="bibr">53</xref></sup> For example, fentanyl is highly lipophilic, facilitating rapid diffusion through membranes, including the blood brain barrier, resulting in a rapid onset of action,<sup><xref rid="CIT0043" ref-type="bibr">43</xref></sup> whereas morphine has a comparatively low lipid solubility resulting in a relatively slower penetration of the blood brain barrier and onset of action.<sup><xref rid="CIT0043" ref-type="bibr">43</xref></sup> The analgesic effect of morphine, the archetypal opioid analgesic, is mainly caused by its metabolite, morphine-6-glucuronide (M6G) instead of the parent compound.<sup><xref rid="CIT0057" ref-type="bibr">57</xref></sup> In preparation for subsequent renal elimination, morphine undergoes metabolism in the liver to morphine-3-glucuronide (M3G) (90%) and M6G (10%) by UDP-glucuronosyltransferases (specifically UGT2B7).<sup><xref rid="CIT0058" ref-type="bibr">58</xref></sup> Although lacking analgesic efficacy, the major metabolite (M3G) should not go unconsidered. M3G is centrally active and attributed to many unfavorable effects related to behavior, dependency, hyperalgesia, and potentially even opposing analgesia.<sup><xref rid="CIT0059" ref-type="bibr">59</xref></sup> Both M6G and M3G accumulate in renal insufficiency. The accumulation of M6G in patients with renal insufficiency has been implicated in morphine toxicity, and the dose of morphine should be adjusted according to the patient&#8217;s current kidney function.<sup><xref rid="CIT0057" ref-type="bibr">57</xref>,<xref rid="CIT0060" ref-type="bibr">60</xref></sup> Structural differences between opioids also contribute to differences in metabolism.<sup><xref rid="CIT0061" ref-type="bibr">61</xref></sup> As previously mentioned, patients&#8217; genetic polymorphisms can vary their ability to metabolize different opioids, accordingly. Altered metabolism can either lead to opioid or metabolite being excreted too rapidly, not reaching its therapeutic effect, or prolonged elimination, producing toxic effects.<sup><xref rid="CIT0061" ref-type="bibr">61</xref></sup> Increased potency and selectivity at the mOR can also contribute to the likelihood of overdose and abuse potential.<sup><xref rid="CIT0062" ref-type="bibr">62</xref></sup></p></sec><sec id="s5"><title>Multi-receptor Ligands</title><p>Focusing on the search for opioids with improved side effect profile and low abuse potential, several novel approaches have emerged. One such approach has led to the development of multi-opioid receptor ligands, simultaneously targeting mOR/kOR, mOR/NOR or mOR/DOR.<sup><xref rid="CIT0063" ref-type="bibr">63</xref></sup> Although compounds simultaneously targeting mOR and kOR, either as agonist/agonist or agonist/antagonist, have shown some clinical efficacy, the limitations associated with the mOR activation, such as potential abuse liability, constipation, and respiratory depression, still remain.<sup><xref rid="CIT0063" ref-type="bibr">63</xref></sup> Most progress has been made in the development of mOR/NOR bifunctional agonists. Compounds with affinity for both NOR and mOR are under development in the &#8220;proof of concept&#8221; stage. These compounds may have a useful profile as analgesics with a reduced addiction liability and a slower development to tolerance.<sup><xref rid="CIT0063" ref-type="bibr">63</xref></sup></p></sec><sec id="s6"><title>Biased Agonism</title><p>Much of the knowledge of GPCR inner workings comes from decades of groundbreaking work from groups like Drs. Lefkowitz and Kobilka.<sup><xref rid="CIT0064" ref-type="bibr">64&#8211;67</xref></sup> Work so profound, their group was awarded the Nobel Prize in Chemistry in 2012.<sup><xref rid="CIT0068" ref-type="bibr">68</xref>,<xref rid="CIT0069" ref-type="bibr">69</xref></sup> As described earlier, in addition to signaling through G proteins, GPCRs can also activate G-protein-independent signaling pathways through multi-functional adaptor proteins called arrestins. GPCRs exist in multiple conformational states, where each conformation confers different downstream effects.<sup><xref rid="CIT0037" ref-type="bibr">37</xref></sup> While the downstream signaling cascades of G-protein contribute to antinociception, ubiquitously expressed arrestins, particularly arrestin-3 (&#946;-arrestin2), play a role in GPCR internalization and desensitization, diminishing G-protein-mediated signaling.<sup><xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0070" ref-type="bibr">70</xref></sup> Following activation, GPCRs are phosphorylated by members of the family of G-protein&#8211;coupled receptor kinases (GRKs). Phosphorylated receptors are then bound by arrestins, which prevent further stimulation of G proteins and downstream signaling pathways.<sup><xref rid="CIT0071" ref-type="bibr">71</xref></sup> In addition, the GRK-arrestin system facilitates GPCR internalization of inactivated receptors, reducing the presence of mOR at the post-synaptic surface through a beta arrestin-mediated mechanism.<sup><xref rid="CIT0071" ref-type="bibr">71</xref></sup> Through this mechanism, repeated signaling of the mOR becomes less effective over time, due to agonism of the endogenous arrestin pathway.<sup><xref rid="CIT0039" ref-type="bibr">39</xref></sup> &#946;-arrestin-2 is also known to regulate GI, respiratory function, and subjective effects (ie, liking, dependence, and withdrawal); however, the mechanisms are unknown.<sup><xref rid="CIT0070" ref-type="bibr">70</xref></sup></p><p>The concept that biased agonists at the mOR might provide a therapeutic advantage favoring effective analgesia stems from observations in &#946;-arrestin-2 knockout mice.<sup><xref rid="CIT0072" ref-type="bibr">72</xref>,<xref rid="CIT0073" ref-type="bibr">73</xref></sup> In &#946;-arrestin-2 knockout mice, morphine was less prone to receptor desensitization and tolerance, providing increased analgesia and causing less respiratory depression and constipation.<sup><xref rid="CIT0072" ref-type="bibr">72</xref>,<xref rid="CIT0073" ref-type="bibr">73</xref></sup> Such findings supported efforts to design agonists with bias toward G-protein-mediated signaling which may result in improved therapeutic index (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3:</label><caption><p>
<bold>Hypothesis for the G Protein-Biased Ligands at the Mu-opioid Receptor.</bold> Unbiased or non-biased agonists (ligands) can efficiently activate both G protein- and &#946;-arrestin-dependent signaling. In contrast, biased agonists at the mu opioid receptor (mOR) preferentially activate G-protein signaling and may offer increased analgesia with improved safety and tolerability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="irad004_fig3.jpg"/></fig><p>Biased agonism can also occur at other GPCRs, such as DOR and kOR. It has been postulated that G-protein&#8211;biased agonists of the DOR may offer an approach to develop analgesics for chronic pain states and therapeutic agents to treat emotional disorders such as depression with a reduced AE profile.<sup><xref rid="CIT0074" ref-type="bibr">74</xref></sup> Likewise, G-protein-biased kappa agonists are hypothesized to reduce pain and itch, with fewer side effects such as anhedonia and psychosis; and research is underway exploring the potential development of G-protein-biased kappa agonists as adjuvant analgesics with reduced addictive potential.<sup><xref rid="CIT0075" ref-type="bibr">75</xref></sup> The research in the biased-ligand technology focusing on the mOR is much more advanced than the DOR and kOR. Oliceridine is the first G-protein agonist at the mOR, developed utilizing biased-ligand technology,<sup><xref rid="CIT0070" ref-type="bibr">70</xref></sup> and is currently FDA approved for the management of acute pain severe enough to require IV opioid analgesia.</p></sec></sec><sec id="s7"><title>Oliceridine</title><sec id="s8"><title>Nonclinical Data</title><p>TRV130, or oliceridine, was discovered as a result of high-throughput screening from a chemical library.<sup><xref rid="CIT0070" ref-type="bibr">70</xref></sup> In human embryonic kidney cells, oliceridine was found to be more potent for G-protein stimulation (EC<sub>50</sub> = 8 nM vs. 50 nM for morphine) but with only 14% of the efficacy of morphine for &#946;-arrestin-2 recruitment, correlating with minimal mOR internalization.<sup><xref rid="CIT0050" ref-type="bibr">50</xref></sup> Additionally, cell-based assays revealed oliceridine to be approximately 400-fold selective for the mOR than the kOR, DOR, and NOR, while morphine was only 10-fold selective for the mOR over the kOR and DOR subtypes.<sup><xref rid="CIT0050" ref-type="bibr">50</xref></sup> Oliceridine demonstrated approximately 3-fold preference for the G-protein pathway over &#946;-arrestin-2 relative to fentanyl.<sup><xref rid="CIT0050" ref-type="bibr">50</xref></sup><italic toggle="yes">In vivo</italic> studies in mice models showed oliceridine is a potent analgesic and causes less GI dysfunction and respiratory suppression than morphine at equianalgesic doses.<sup><xref rid="CIT0050" ref-type="bibr">50</xref></sup> In the animal models, the antinociceptive effect of oliceridine can be antagonized by the opioid antagonist naloxone. Another study, using a murine model, reported less tolerance and opioid-induced hyperalgesia with oliceridine as compared to morphine.<sup><xref rid="CIT0076" ref-type="bibr">76</xref></sup> However, a study utilizing repeated administration of oliceridine showed constipating effects in mice and abuse potential similar to that of morphine and other mu-opioid agonists.<sup><xref rid="CIT0077" ref-type="bibr">77</xref></sup></p><p>Recent research utilizing cell-based assays or mutant strains, different than those used by DeWire et al.<sup><xref rid="CIT0050" ref-type="bibr">50</xref></sup> found oliceridine to have a low intrinsic efficacy and attributed the favorable therapeutic window and reduced AEs (eg, respiratory depression) to partial agonism, similar to that observed with buprenorphine.<sup><xref rid="CIT0078" ref-type="bibr">78</xref></sup> In a re-analysis of these findings, Stahl and Bohn clarified that the determination of &#8220;intrinsic efficacy&#8221; or &#8220;biased agonism&#8221; is dependent on the cellular signaling systems (ie, receptor density, effector expression, and amplification of signal), as well as reference agonist used; and the differing cellular systems can contribute to the diverse signaling profiles.<sup><xref rid="CIT0079" ref-type="bibr">79</xref></sup> These authors concluded that oliceridine is a biased agonist for G protein signaling through partial agonism in both G-protein signaling and &#946;-arrestin-2 recruitment with the intrinsic efficacy uncoupled from biased agonism, contributing to the improved therapeutic window.<sup><xref rid="CIT0079" ref-type="bibr">79</xref></sup></p></sec><sec id="s9"><title>Clinical Pharmacokinetics</title><p>When administered IV over 1 minute to 1 hour, oliceridine exhibited a half-life (t&#189;) of approximately 1.5 to 3 hours.<sup><xref rid="CIT0080" ref-type="bibr">80</xref></sup> The mean steady-state volume of distribution of oliceridine ranges between 90-120 L, indicating extensive tissue distribution, and the plasma protein binding of oliceridine is 77%. Oliceridine undergoes extensive hepatic metabolism by both cytochrome P450 (CYP) enzymes CYP2D6 and CYP3A4 with each enzyme contributing equally.<sup><xref rid="CIT0080" ref-type="bibr">80</xref></sup> Importantly, none of the metabolites are pharmacologically active.<sup><xref rid="CIT0080" ref-type="bibr">80</xref></sup> Mean oliceridine clearance in subjects with end stage renal failure (49.2 L/h) was 81.2% of that observed in healthy subjects (55.3 L/h), demonstrating doses do not need to be adjusted in patients with renal impairment.<sup><xref rid="CIT0081" ref-type="bibr">81</xref></sup> The volume of distribution increases with liver dysfunction. Although no dose adjustment is necessary for patients with mild or moderate hepatic impairment, patients with severe impairment may require an initial dose reduction followed by fewer subsequent doses of oliceridine, as a longer half-life is observed.<sup><xref rid="CIT0081" ref-type="bibr">81</xref></sup></p></sec><sec id="s10"><title>Early Clinical Studies</title><p>An early phase 1 study of oliceridine in healthy human volunteers, compared to morphine, showed superior analgesia in experimental cold pain test (CPT).<sup><xref rid="CIT0082" ref-type="bibr">82</xref></sup> Oliceridine, administered IV at bolus doses of 1.5 mg, 3 mg, and 4.5 mg elicited rapid and significant increases in CPT hand removal latency from baseline with peak efficacy 10 minutes post-dose. The geometric means were 81, 106, and 116 seconds for oliceridine (1.5 mg, 3 mg, and 4.5 mg, respectively), vs 41 seconds for placebo (<italic toggle="yes">p</italic> &lt; .0001), and 75 seconds for morphine 10 mg (<italic toggle="yes">p</italic> &lt; .02 vs oliceridine 3 mg and 4.5 mg). Oliceridine 1.5 mg IV produced similar analgesia as morphine 10 mg IV.<sup><xref rid="CIT0082" ref-type="bibr">82</xref></sup> All doses of oliceridine had a significantly lower effect on respiratory drive (as measured by ventilatory response to hypercapnia) than morphine (&#8722;7.3, &#8722;7.6, and &#8722;9.4 h&#183;min/L for oliceridine 1.5, 3, and 4.5 mg, respectively, vs &#8722;15.9 h&#183;min/L for morphine 10 mg; each <italic toggle="yes">p</italic> &lt; .05 vs morphine). Incidence of nausea was also less with oliceridine than morphine.<sup><xref rid="CIT0082" ref-type="bibr">82</xref>,<xref rid="CIT0083" ref-type="bibr">83</xref></sup></p></sec><sec id="s11"><title>Phase 2 Studies</title><p>In a phase 2 randomized, double-blind, adaptive-design, fixed-dose study in patients experiencing post-operative pain after bunionectomy, median onset of analgesia was 1-2 minutes with oliceridine 2-3 mg IV after the first dose (6 minutes with morphine 4 mg IV), as measured by two-stopwatch method.<sup><xref rid="CIT0084" ref-type="bibr">84</xref></sup> Meaningful pain relief with oliceridine occurred in under 5 minutes. No serious adverse events (SAEs) were reported. The most frequent adverse reactions reported in all active treatment groups were dose-dependent nausea, dizziness, headache, and vomiting.<sup><xref rid="CIT0084" ref-type="bibr">84</xref></sup></p><p>A phase 2b study conducted in patients undergoing abdominoplasty utilized a patient-controlled analgesia (PCA) regimen: two 0.75 mg loading doses of oliceridine separated by 10 minutes, followed by 0.1 mg demand doses, increased to 0.35 mg, compared to morphine PCA treatment regimen consisting of two 2 mg loading doses separated by 10 minutes followed by 1 mg demand doses.<sup><xref rid="CIT0085" ref-type="bibr">85</xref></sup> Similar analgesia was observed with oliceridine and morphine (vs placebo), with lower incidence of nausea (41% and 46% with oliceridine 0.1 mg and 0.35 mg demand dose, respectively, vs 72% with morphine; <italic toggle="yes">p</italic> &lt; .01) and vomiting (15% with both oliceridine demand dose regimens vs 42% with morphine; <italic toggle="yes">p</italic> &lt; .01).<sup><xref rid="CIT0085" ref-type="bibr">85</xref></sup> Additionally, respiratory events (hypoventilation and respiratory depression) were also significantly lower with both oliceridine regimens (15% with 0.1 mg demand dose, and 31% with 0.35 mg demand dose) vs morphine regimen (53%, <italic toggle="yes">p</italic> &lt; .05 for both oliceridine regimens vs morphine).<sup><xref rid="CIT0085" ref-type="bibr">85</xref></sup></p></sec><sec id="s12"><title>Phase 3 Studies</title><p>The three pivotal phase 3 studies, including two randomized placebo- and morphine-controlled trials (APOLLO studies)<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> and an open-label, safety study (ATHENA)<sup><xref rid="CIT0088" ref-type="bibr">88</xref></sup> were key to the FDA approval of oliceridine for use in severe acute pain. These studies evaluated oliceridine in over 1,500 patients with moderate-to-severe acute pain; however, no patients with burn injury were enrolled.</p><sec id="s13"><title>Randomized controlled clinical studies</title><p>In the two randomized, double-blind, placebo- and morphine- controlled studies in patients with moderate-to-severe acute pain following either orthopedic surgery-bunionectomy (APOLLO-1; <italic toggle="yes">N</italic> = 389) or plastic surgery-abdominoplasty (APOLLO-2; <italic toggle="yes">N</italic> = 401),<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> patients with a numeric (pain) rating scale (NRS 0 to 10; 10 being the worst pain imaginable) score &#8805;4 (bunionectomy) or &#8805;5 (abdominoplasty) were randomized to receive one of five demand-dose (PCA) regimens: oliceridine 0.1 mg, 0.35 mg, or 0.5 mg; a morphine-control of 1 mg; or a volume-matched placebo dose. Patients were treated for up to 48 hours in APOLLO-1 and for up to 24 hours in APOLLO-2. The loading dose for all oliceridine treatment regimens was 1.5 mg; demand doses were 0.1, 0.35, or 0.5 mg, according to assigned treatment group. Supplemental doses of 0.75 mg were permitted, beginning 1 hour after the loading dose, and hourly thereafter, as needed. The loading dose for the morphine treatment regimen was 4 mg; the demand dose was 1 mg; and supplemental doses of 2 mg were permitted, beginning 1 hour after the loading dose, and hourly after, as needed. A lockout interval of 6 minutes was used for all PCA regimens. Etodolac 200 mg every 6 hours as needed was allowed, as the rescue medication. No other multimodal analgesia was included in these studies.<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> The primary efficacy end point was treatment responders (vs placebo); defined as: meeting &#8805;30% improvement in time-weighted sum of pain intensity difference from baseline at 48 h (APOLLO-1) or 24 h (APOLLO-2) with no use of rescue pain medications, no early discontinuation of study medication, and not reaching protocol-specified dosing limit.<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> The maximum allowable dosing limit for both studies was to not exceed 60 mg in the first 12 hours.</p><p>Responder rates were 50, 62, and 65.8% in the 0.1, 0.35, and 0.5 mg regimens, respectively (all <italic toggle="yes">p</italic> &lt; .0001 vs placebo, 15.2%) in the bunionectomy study (APOLLO-1) and 61, 76.3, and 70.0% for the three demand dose regimens, respectively, (<italic toggle="yes">p</italic> &lt; .05 vs placebo, 45.7%) in the abdominoplasty study (APOLLO-2). The responder rate for morphine was 71.1% (<italic toggle="yes">p</italic> &lt; .001 vs placebo) in the bunionectomy study and 78.3% (<italic toggle="yes">p</italic> &lt; .001 vs placebo) in the abdominoplasty study. In both studies, exploratory analyses indicated that the oliceridine 0.35 mg and 0.5 mg demand dose regimens were noninferior to morphine 1 mg demand dose.<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup></p><p>A key secondary end point in both studies was the respiratory safety burden (RSB), defined as the mathematical product of the incidence of a defined set of observed respiratory safety events (RSE) multiplied by the mean expected cumulative duration of these events (in hours).<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> The RSEs measured were clinically relevant changes in respiratory rate, oxygen saturation, and sedation (measured using the Moline-Roberts Pharmacologic Sedation Scale). The RSB and RSE measures were numerically lower for each oliceridine demand dose regimen compared to morphine although statistical significance was not reached (<xref rid="F4" ref-type="fig">Figure 4</xref><bold>).</bold> Of note, event rates were lower than <italic toggle="yes">a priori</italic> anticipation utilized to guide sample size determination, and thus enrollment was not sufficient to exclude a difference that may exist.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4:</label><caption><p>
<bold>Respiratory Safety of Oliceridine in Phase 3 Randomized Clinical Trials (Adapted from Gan and Wase 2020).</bold> Respiratory safety burden (RSB) and respiratory safety events (RSE) in pivotal Phase 3 studies of oliceridine.<sup><xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></sup> RSB was calculated as the mathematical product of the incidence of respiratory safety events and the mean duration of such events in affected patients. No statistically significant differences for any of the oliceridine treatment groups vs. morphine. RSEs were changes in respiratory rate, oxygen saturation (SpO<sub>2</sub> &lt; 90%), and sedation measured using the Moline-Roberts Pharmacologic Sedation Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="irad004_fig4.jpg"/></fig><p>In both studies, where prophylactic antiemetics were not permitted, GI adverse events (nausea, vomiting) appeared to be numerically lower with oliceridine than morphine. Analyzing the pooled data (ie, improving power for statistical comparison) from both phase 3 randomized controlled studies, the incidence of nausea was lower with oliceridine 0.1 mg (40%) and 0.35 mg (59%) demand doses than with morphine 1 mg (70%) demand doses with a significant risk reduction of 43% (0.1 mg demand dose vs morphine, <italic toggle="yes">p</italic> &lt; .001). Likewise, the incidence of vomiting was also lower with all demand doses of oliceridine: 20% with 0.1 mg, 30% with 0.35 mg and 42% with 0.5 mg, than with morphine 1 mg (52%); with a 41-61% significantly lower relative risk observed with the 0.1 mg and 0.35 mg demand dose (<italic toggle="yes">p</italic> &lt; .001 vs. morphine).<sup><xref rid="CIT0080" ref-type="bibr">80</xref>,<xref rid="CIT0089" ref-type="bibr">89</xref></sup></p><p>To further characterize the GI tolerability, an exploratory analysis evaluated the composite endpoint of complete GI response (defined as no vomiting and no use of rescue antiemetics), using a logistic regression model. In this analysis, a higher proportion of oliceridine-treated patients achieved a complete GI response than morphine-treated patients. Furthermore, after adjustment for equianalgesic conditions, the odds ratio to experience complete GI response with oliceridine (combined demand doses) vs morphine was 3.14 (95% CI: 1.78, 5.56; <italic toggle="yes">p</italic> &lt; .0001) and 1.92 (95% CI: 1.09, 3.36; <italic toggle="yes">p</italic> = .024) in the bunionectomy and abdominoplasty studies, respectively.<sup><xref rid="CIT0089" ref-type="bibr">89</xref></sup></p></sec><sec id="s14"><title>Open-label safety study</title><p>The phase 3 multicenter, open-label study, ATHENA, evaluated the safety and effectiveness of oliceridine in moderate-to-severe acute pain in post-surgical and non-surgical medical settings.<sup><xref rid="CIT0088" ref-type="bibr">88</xref></sup> A total of 768 patients aged 18 years and older (mean age 54.1 years) with surgical or non-surgical pain rated &#8805;4 on an 11-point NRS received at least one dose of IV oliceridine either by clinician administered bolus or PCA. The study population was mainly in a surgical setting (94%), with orthopedic (30%), colorectal (15%) or gynecologic (15%) procedures being the most common surgical types. This study also enrolled 60 patients (8%) undergoing plastic surgery, including 3 patients with wound closure unrelated to burn (i.e., 1 patient with a skin cosmetic procedure and 2 patients with skin grafting). Thirty-two percent of the patients were aged 65 years or older, 46% had a BMI &#8805; 30 kg/m<sup>2</sup>, and each patient had at least one comorbidity. Bolus dosing was initiated at 1-2 mg with an optional additional 1 mg dose after 15 min, followed by 1&#8211;3 mg doses every 1-3 h as needed. In the emergency department and post-anesthesia care units, loading doses of 1&#8211;3 mg were followed by supplemental 1&#8211;3 mg doses every 5 min as needed. For PCA, the loading dose was 1.5 mg followed by demand doses of 0.5 mg with a lockout interval of 6 min. Supplemental doses of 1 mg were allowed. Treatment duration for each patient was based on the individual clinical need, and the protocol limited the maximal duration of oliceridine treatment to 14 days.<sup><xref rid="CIT0088" ref-type="bibr">88</xref></sup> Unlike the randomized controlled studies, prophylactic antiemetics and multimodal non-opioid analgesics were allowed and overall, 84% of patients received oliceridine as a part of multimodal analgesic regimen. The median cumulative dose was 19.3 mg, ranging from 0.9 to 223.5 mg. The median cumulative duration of exposure was 20.3 hours, ranging from 0 hours (for patients who received a single dose) to 142.7 hours (~6 days).<sup><xref rid="CIT0088" ref-type="bibr">88</xref></sup> No deaths or significant cardiorespiratory events were reported. Serious adverse events were reported in 26 patients (3%). Most SAEs were due to surgical complications, secondary to underlying medical condition. All SAEs resolved or were resolving at the time of study completion. Only 3 patients experienced SAEs determined by the investigator to be &#8220;possibly related&#8221; to oliceridine (ie, post-operative ileus, respiratory depression with respiratory rate &lt; 8 breaths per minute, hepatic/renal failure which was confounded by surgical complications). It is noteworthy that no patients received naloxone for reversal of any respiratory event while receiving oliceridine. The most common AEs were nausea (31%), constipation (11%) and vomiting (10%) (<xref rid="T2" ref-type="table">Table 2</xref>). Pruritus incidence (an important consideration for treating patients with burn injury) was less than 5%. A good indicator of respiratory event risk, somnolence/sedation was reported in less than 2% of patients; and at the end of the study, 93% of patients self-reported &#8220;none to minimal&#8221; sedation. Opioid induced respiratory depression (OIRD), defined as oxygen saturation &lt; 90%, occurred in 6% of patients. In an exploratory analysis of just the 724 surgical patients in the ATHENA study, the incidence of OIRD was 13.7% using a broader definition (SpO<sub>2</sub> &lt; 90% in 5.2% and respiratory rate &lt; 10 bpm in 9.3%), and advanced age (ie, &#8805; 65 years of age) and/or increased BMI (&#8805; 30 kg/m<sup>2</sup>) was not associated with increased risk of OIRD.<sup><xref rid="CIT0090" ref-type="bibr">90</xref></sup></p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2:</label><caption><p>Summary of adverse events reported in the Phase 3 open-label safety trial, ATHENA (<italic toggle="yes">Bergese et al. 2019</italic>)</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">All Patients<break/><italic toggle="yes">N</italic> = 768<break/>n (%)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Patients with at least one AE</td><td align="center" rowspan="1" colspan="1">490 (63.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">Patients with at least one SAE</td><td align="center" rowspan="1" colspan="1">26 (3.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">Patients with at least one AE leading to early study medication discontinuation</td><td align="center" rowspan="1" colspan="1">17 (2.2)</td></tr><tr><td align="center" rowspan="1" colspan="1">Possibly or probably related to study drug</td><td align="center" rowspan="1" colspan="1">256 (33.3)</td></tr><tr><td align="center" colspan="2" rowspan="1">Most Common AEs (&#8805;5%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Nausea</td><td align="center" rowspan="1" colspan="1">239 (31.1)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Constipation</td><td align="center" rowspan="1" colspan="1">84 (10.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Vomiting</td><td align="center" rowspan="1" colspan="1">80 (10.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Pruritus</td><td align="center" rowspan="1" colspan="1">38 (4.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hypokalemia</td><td align="center" rowspan="1" colspan="1">36 (4.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Dizziness</td><td align="center" rowspan="1" colspan="1">34 (4.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Headache</td><td align="center" rowspan="1" colspan="1">34 (4.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hypotension</td><td align="center" rowspan="1" colspan="1">28 (3.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Insomnia</td><td align="center" rowspan="1" colspan="1">28 (3.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Pyrexia</td><td align="center" rowspan="1" colspan="1">25 (3.3)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hypocalcemia</td><td align="center" rowspan="1" colspan="1">24 (3.1)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hypophosphatemia</td><td align="center" rowspan="1" colspan="1">23 (3.0)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Procedural Nausea</td><td align="center" rowspan="1" colspan="1">21 (2.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Flatulence</td><td align="center" rowspan="1" colspan="1">20 (2.6)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Somnolence</td><td align="center" rowspan="1" colspan="1">6 (0.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Sedation</td><td align="center" rowspan="1" colspan="1">8 (1.0)</td></tr></tbody></table><table-wrap-foot><fn id="T2Fn1"><p>Note: <italic toggle="yes">AE</italic>, adverse event; <italic toggle="yes">SAE</italic>, serious adverse event.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s15"><title>Implications and Future Direction</title><p>As discussed, both anecdotes and evidence-supported guidelines for managing pain in patients with burn injuries is fraught with failure. Till date, there has been no overwhelmingly positive finding to offer total relief to such a patient. There is no good answer. But there is hope. Preclinical work and the science supporting biased-ligands and oliceridine&#8217;s development bring new optimism to patients with burn injuries and providers charged with their care. Although no patient with burn injury was enrolled in the oliceridine clinical studies, findings from the phase 2 and randomized, controlled phase 3 studies have established that oliceridine is a potent analgesic. Additionally, findings from the phase 3 open-label safety study and pooled and exploratory analyses, suggest a potentially improved respiratory and GI safety profile associated with oliceridine. In addition, the low incidence rate of pruritus and somnolence/sedation observed in the phase 3 open-label safety study makes oliceridine a potentially attractive option for use in the management of pain after burn injury. With these considerations, the RELIEVE phase 4 case-controlled study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05465226">NCT05465226</ext-link>) is currently exploring efficacy, safety, and the pharmacokinetics of oliceridine specifically for patients with burn injuries who require opioid treatment for their acute severe pain. With continued investment in research (i.e., the RELIEVE trial) and efforts, an answer may be found to offer future patients a better solution.</p></sec></body><back><ack id="a1"><title>ACKNOWLEDGEMENT</title><p>Authors would like to thank Kanaka Sridharan, MS, RPh, employee at Trevena, Inc. at the time of this work, for editorial support; and Innovation Communications Group, Inc., New York, NY, for assistance with figures.</p></ack><notes id="n1"><p>
<bold>Conflicts of Interest and Source of Funding.</bold> There was no funding for this review. Trevena, Inc paid open access fees. DH is a consultant for Trevena, Inc. and has participated in the development of investigator-initiated trials supported by Trevena, Inc. DH is a consultant for Medline Industries, LP. EDB is an employee at Trevena, Inc.</p></notes><ref-list id="r1"><title>REFERENCES</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Holtman</surname><given-names>JR</given-names>, <suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Jellish</surname><given-names>WS.</given-names></string-name></person-group><article-title>Opioid-induced hyperalgesia and burn pain</article-title>. <source>J Burn Care Res</source><year>2012</year>;<volume>33</volume>:<fpage>692</fpage>&#8211;<lpage>701</lpage>.<pub-id pub-id-type="pmid">23143613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BCR.0b013e31825adcb0</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Romanowski</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Carson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pape</surname><given-names>K</given-names></string-name><etal>et al.</etal></person-group><article-title>American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient: a review of the literature, a compilation of expert opinion and next steps</article-title>. <source>J Burn Care Res</source><year>2020</year>;<volume>41</volume>:<fpage>11291152</fpage>&#8211;<lpage>1151</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/iraa120</pub-id><pub-id pub-id-type="pmcid">PMC7703674</pub-id><pub-id pub-id-type="pmid">32885252</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>James</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Jowza</surname><given-names>M.</given-names></string-name></person-group><article-title>Principles of burn pain management</article-title>. <source>Clin Plast Surg</source><year>2017</year>;<volume>44</volume>:<fpage>737</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">28888299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cps.2017.05.005</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jeschke</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>van Baar</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Choudhry</surname><given-names>MA</given-names></string-name><etal>et al.</etal></person-group><article-title>Burn injury</article-title>. <source>Nat Rev Dis Primers</source><year>2020</year>;<volume>6</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">32054846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-020-0145-5</pub-id><pub-id pub-id-type="pmcid">PMC7224101</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patterson</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Drever</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Soltani</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group><article-title>A comparison of interactive immersive virtual reality and still nature pictures as distraction-based analgesia in burn wound care</article-title>. <source>Burns</source><year>2023</year>;<volume>49</volume>:<fpage>182</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">35305845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2022.02.002</pub-id><pub-id pub-id-type="pmcid">PMC9363532</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kabuk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>&#350;endir</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Filinte</surname><given-names>G.</given-names></string-name></person-group><article-title>The effect of reflexology massage and passive music therapy intervention before burn dressing on pain, anxiety level and sleep quality</article-title>. <source>Burns</source><year>2022</year>;<volume>48</volume>:<fpage>1743</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">34955298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2021.10.012</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akg&#252;l</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Karakul</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alt&#305;n</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Effectiveness of lavender inhalation aromatherapy on pain level and vital signs in children with burns: a randomized controlled trial</article-title>. <source>Complement Ther Med</source><year>2021</year>;<volume>60</volume>:<fpage>102758</fpage>.<pub-id pub-id-type="pmid">34229085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctim.2021.102758</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Froutan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tavousi</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Sedaghat</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sadeghnia</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Layegh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mazlom</surname><given-names>SR.</given-names></string-name></person-group><article-title>The effect of inhalation aromatherapy on sedation level, analgesic dosage, and bispectral index values during donor site dressing in patients with burns: a randomized clinical trial</article-title>. <source>Adv Skin Wound Care</source><year>2022</year>;<volume>35</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ASW.0000801544.79621.24</pub-id><pub-id pub-id-type="pmid">34935724</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loskotova</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Loskotova</surname><given-names>J.</given-names></string-name></person-group><article-title>The use of acupuncture in first aid of burns-Clinical report</article-title>. <source>Burns</source><year>2017</year>;<volume>43</volume>:<fpage>1782</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28818334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2017.04.025</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hill</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Ly</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Desai</surname><given-names>J</given-names></string-name><etal>et al.</etal></person-group><article-title>Efficacy of a novel LAM femoral cutaneous block technique for acute donor site pain</article-title>. <source>J Burn Care Res</source><year>2023</year>;<volume>44</volume>:<fpage>16</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36270008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/irac159</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Artz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>MA</given-names>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>MVP</given-names></string-name><etal>et al.</etal></person-group><article-title>Intraoperative liposomal bupivacaine for skin graft donor site analgesia: a retrospective cohort study</article-title>. <source>Burns</source><year>2021</year>;<volume>47</volume>:<fpage>1045</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">34034954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2020.06.011</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lintner</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Brennan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Miles</surname><given-names>MVP</given-names></string-name><etal>et al.</etal></person-group><article-title>Oral administration of injectable ketamine during burn wound dressing changes</article-title>. <source>J Pharm Pract</source><year>2021</year>;<volume>34</volume>:<fpage>423</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31537149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0897190019876497</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boyd</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Blair</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Degenkolb</surname><given-names>KE</given-names></string-name><etal>et al.</etal></person-group><article-title>A prospective analysis describing the innovative use of liposomal bupivacaine in burn patients</article-title>. <source>Burns</source><year>2020</year>;<volume>46</volume>:<fpage>370</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">31420265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2019.07.031</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mewa Kinoo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>B.</given-names></string-name></person-group><article-title>Complex regional pain syndrome in burn pathological scarring: a case report and review of the literature</article-title>. <source>Burns</source><year>2017</year>;<volume>43</volume>:<fpage>e47</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">28314473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2017.02.007</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paggiaro</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Paggiaro</surname><given-names>PBS</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>RAQ</given-names></string-name>, <string-name name-style="western"><surname>Freitas</surname><given-names>NO</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>VF</given-names></string-name>, <string-name name-style="western"><surname>Gemperli</surname><given-names>R.</given-names></string-name></person-group><article-title>Posttraumatic stress disorder in burn patient: a systematic review</article-title>. <source>J Plast Reconstr Aesthet Surg</source><year>2022</year>;<volume>75</volume>:<fpage>1586</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">35361563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bjps.2022.02.052</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Griggs</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Goverman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bittner</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Levi</surname><given-names>B.</given-names></string-name></person-group><article-title>Sedation and pain management in burn patients</article-title>. <source>Clin Plast Surg</source><year>2017</year>;<volume>44</volume>:<fpage>535</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28576242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cps.2017.02.026</pub-id><pub-id pub-id-type="pmcid">PMC5642992</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Pruskowski</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Ainsworth</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Linsenbardt</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Rizzo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Cancio</surname><given-names>LC.</given-names></string-name></person-group><article-title>A review of adjunctive therapies for burn injury pain during the opioid crisis</article-title>. <source>J Burn Care Res</source><year>2019</year>;<volume>40</volume>:<fpage>983</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">31259369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/irz111</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Emery</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Eitan</surname><given-names>S.</given-names></string-name></person-group><article-title>Drug-specific differences in the ability of opioids to manage burn pain</article-title>. <source>Burns</source><year>2020</year>;<volume>46</volume>:<fpage>503</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">31859093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2019.03.028</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hill</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Sinclair</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Hickerson</surname><given-names>WL.</given-names></string-name></person-group><article-title>Rational selection and use of antimicrobials in patients with burn injuries</article-title>. <source>Clin Plast Surg</source><year>2017</year>;<volume>44</volume>:<fpage>521</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28576241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cps.2017.02.012</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blanchet</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jullien</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vinsonneau</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tod</surname><given-names>M.</given-names></string-name></person-group><article-title>Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients</article-title>. <source>Clin Pharmacokinet</source><year>2008</year>;<volume>47</volume>:<fpage>635</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">18783295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200847100-00002</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bittner</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Shank</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Woodson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Martyn</surname><given-names>JAJ.</given-names></string-name></person-group><article-title>Acute and perioperative care of the burn-injured patient</article-title>. <source>Anesthesiology</source><year>2015</year>;<volume>122</volume>:<fpage>448</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">25485468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000559</pub-id><pub-id pub-id-type="pmcid">PMC4844008</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Romanowski</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Sen</surname><given-names>S.</given-names></string-name></person-group><article-title>Wound healing in older adults with severe burns: Clinical treatment considerations and challenges</article-title>. <source>Burns Open</source><year>2022</year>;<volume>6</volume>:<fpage>57</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">35571008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burnso.2022.01.002</pub-id><pub-id pub-id-type="pmcid">PMC9104500</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tapking</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Houschyar</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Rontoyanni</surname><given-names>VG</given-names></string-name><etal>et al.</etal></person-group><article-title>The influence of obesity on treatment and outcome of severely burned patients</article-title>. <source>J Burn Care Res</source><year>2019</year>;<volume>40</volume>:<fpage>996</fpage>&#8211;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">31294797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/irz115</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Hickerson</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Velamuri</surname><given-names>SR.</given-names></string-name></person-group><article-title>Analysis of factors impacting length of stay in thermal and inhalation injury</article-title>. <source>Burns</source><year>2019</year>;<volume>45</volume>:<fpage>1593</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31130323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.burns.2019.04.016</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buckley</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Velamuri</surname><given-names>SR</given-names></string-name><etal>et al.</etal></person-group><article-title>A comprehensive, retrospective analysis of variables for potential mortality impact in patients with thermal or inhalation injury</article-title>. <source>J Burn Care Res</source><year>2023</year>;<volume>44</volume>:<fpage>65</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">35639813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/irac071</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kessler</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gruschkus</surname><given-names>SK</given-names></string-name><etal>et al.</etal></person-group><article-title>Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes</article-title>. <source>Pharmacotherapy</source><year>2013</year>;<volume>33</volume>:<fpage>383</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23553809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.1223</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shafi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Collinsworth</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Copeland</surname><given-names>LA</given-names></string-name><etal>et al.</etal></person-group><article-title>Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system</article-title>. <source>JAMA Surg</source><year>2018</year>;<volume>153</volume>:<fpage>757</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">29799927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2018.1039</pub-id><pub-id pub-id-type="pmcid">PMC6142954</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shahabi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hassan</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Jazani</surname><given-names>NH.</given-names></string-name></person-group><article-title>Post heat shock tolerance: a neuroimmunological anti-inflammatory phenomenon</article-title>. <source>J Inflamm (Lond)</source><year>2009</year>;<volume>6</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">19327140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1476-9255-6-7</pub-id><pub-id pub-id-type="pmcid">PMC2666725</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morgan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deuis</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Fr&#248;sig-J&#248;rgensen</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group><article-title>Burn pain: a systematic and critical review of epidemiology, pathophysiology, and treatment</article-title>. <source>Pain Med</source><year>2018</year>;<volume>19</volume>:<fpage>708</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">29036469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnx228</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chung</surname><given-names>BY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>MJ</given-names></string-name><etal>et al.</etal></person-group><article-title>Post-burn pruritus</article-title>. <source>Int J Mol Sci</source><year>2020</year>;<volume>21</volume>:<fpage>3880</fpage>.<pub-id pub-id-type="pmid">32485929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21113880</pub-id><pub-id pub-id-type="pmcid">PMC7313087</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mehan</surname><given-names>A.</given-names></string-name></person-group><article-title>Addressing opioid tolerance and opioid-induced hypersensitivity: Recent developments and future therapeutic strategies</article-title>. <source>Pharmacol Res Perspect</source><year>2021</year>;<volume>9</volume>:<fpage>e00789</fpage>.<pub-id pub-id-type="pmid">34096178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.789</pub-id><pub-id pub-id-type="pmcid">PMC8181203</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pasternak</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>YX.</given-names></string-name></person-group><article-title>Mu opioids and their receptors: evolution of a concept</article-title>. <source>Pharmacol Rev</source><year>2013</year>;<volume>65</volume>:<fpage>1257</fpage>&#8211;<lpage>317</lpage>.<pub-id pub-id-type="pmid">24076545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.112.007138</pub-id><pub-id pub-id-type="pmcid">PMC3799236</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Olmstead</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>LH.</given-names></string-name></person-group><article-title>Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling</article-title>. <source>Neuroscience</source><year>2005</year>;<volume>135</volume>:<fpage>247</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">16084657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2005.06.003</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khanna</surname><given-names>IK</given-names></string-name>, <string-name name-style="western"><surname>Pillarisetti</surname><given-names>S.</given-names></string-name></person-group><article-title>Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain</article-title>. <source>J Pain Res</source><year>2015</year>;<volume>8</volume>:<fpage>859</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">26672499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S85951</pub-id><pub-id pub-id-type="pmcid">PMC4675640</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>C&#225;ceres-Jerez</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Gomezese-Ribero</surname><given-names>OF</given-names></string-name>, <string-name name-style="western"><surname>Reyes-C&#225;rdenas</surname><given-names>LI</given-names></string-name><etal>et al.</etal></person-group><article-title>Management of acute pain in extensive burn injury: nonsystematic review of the literature</article-title>. <source>Colombian J Anesthesiol</source><year>2018</year>;<volume>46</volume>:<fpage>49</fpage>&#8211;<lpage>54</lpage>.</mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coluzzi</surname><given-names>FF</given-names></string-name>, <string-name name-style="western"><surname>Caputi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Billeci</surname><given-names>D</given-names></string-name><etal>et al.</etal></person-group><article-title>Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists</article-title>. <source>Ther Clin Risk Manag</source><year>2020</year>;<volume>16</volume>:<fpage>821</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">32982255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TCRM.S262843</pub-id><pub-id pub-id-type="pmcid">PMC7490082</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bologna</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Teoh</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bayoumi</surname><given-names>AS</given-names></string-name><etal>et al.</etal></person-group><article-title>Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology</article-title>. <source>Biomol Ther (Seoul)</source><year>2017</year>;<volume>25</volume>:<fpage>12</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28035079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4062/biomolther.2016.165</pub-id><pub-id pub-id-type="pmcid">PMC5207460</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zuo</surname><given-names>Z.</given-names></string-name></person-group><article-title>The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance</article-title>. <source>Anesth Analg</source><year>2005</year>;<volume>101</volume>:<fpage>728</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">16115983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/01.ANE.0000160588.32007.AD</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haberstock-Debic</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>YJ</given-names></string-name><etal>et al.</etal></person-group><article-title>Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons</article-title>. <source>J Neurosci</source><year>2005</year>;<volume>25</volume>:<fpage>7847</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">16120787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5045-04.2005</pub-id><pub-id pub-id-type="pmcid">PMC6725258</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montgomery</surname><given-names>LS.</given-names></string-name></person-group><article-title>Pain management with opioids in adults</article-title>. <source>J Neurosci Res</source><year>2022</year>;<volume>100</volume>:<fpage>10</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32770580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.24695</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="book"><collab>National Academies of Sciences, Engineering, and Medicine; Health and Medicvine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse</collab>, <etal>et al.</etal><source>Pain management and the Opioid epidemic: balancing societal and individual benefits and risks of prescription Opioid use</source>. <publisher-loc>Washington (DC)</publisher-loc>: <publisher-name>National Academies Press (US)</publisher-name>. Copyright 2017 by the National Academy of Sciences. All rights reserved; <year>2017</year>.<pub-id pub-id-type="pmid">29023083</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Rettig</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Yarmolinsky</surname><given-names>A</given-names></string-name></person-group>; <collab>Institute of Medicine Committee on Federal Regulation of Methadone, T.</collab><source>Federal regulation of methadone treatment</source>. <publisher-loc>Washington (DC)</publisher-loc>: <publisher-name>National Academies Press (US)</publisher-name>. Copyright 1995 by the National Academy of Sciences. All rights reserved; <year>1995</year>.<pub-id pub-id-type="pmid">25121195</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pathan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>J.</given-names></string-name></person-group><article-title>Basic opioid pharmacology: an update</article-title>. <source>Br J Pain</source><year>2012</year>;<volume>6</volume>:<fpage>11</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">26516461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2049463712438493</pub-id><pub-id pub-id-type="pmcid">PMC4590096</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Machelska</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Celik</surname><given-names>M.</given-names></string-name></person-group><article-title>Advances in achieving opioid analgesia without side effects</article-title>. <source>Front Pharmacol</source><year>2018</year>;<volume>9</volume>:<fpage>1388</fpage>.<pub-id pub-id-type="pmid">30555325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.01388</pub-id><pub-id pub-id-type="pmcid">PMC6282113</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McDonald</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>DF.</given-names></string-name></person-group><article-title>Opioid receptors</article-title>. <source>Continuing Educ Anaesthesia Crit Care Pain</source><year>2005</year>;<volume>5</volume>:<fpage>22</fpage>&#8211;<lpage>5</lpage>.</mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trescot</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Datta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group><article-title>Opioid pharmacology</article-title>. <source>Pain Physician</source><year>2008</year>;<volume>11</volume>:<fpage>S133</fpage>&#8211;<lpage>153</lpage>.<pub-id pub-id-type="pmid">18443637</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pradhan</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Befort</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nozaki</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gav&#233;riaux-Ruff</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kieffer</surname><given-names>BL.</given-names></string-name></person-group><article-title>The delta opioid receptor: an evolving target for the treatment of brain disorders</article-title>. <source>Trends Pharmacol Sci</source><year>2011</year>;<volume>32</volume>:<fpage>581</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21925742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2011.06.008</pub-id><pub-id pub-id-type="pmcid">PMC3197801</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galligan</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Sternini</surname><given-names>C.</given-names></string-name></person-group><article-title>Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance</article-title>. <source>Handb Exp Pharmacol</source><year>2017</year>;<volume>239</volume>:<fpage>363</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">28204957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/164_2016_116</pub-id><pub-id pub-id-type="pmcid">PMC6310692</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johnson</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Kinney</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wiegel</surname><given-names>LM.</given-names></string-name></person-group><article-title>Inhibitory and excitatory effects of micro-, delta-, and kappa-opioid receptor activation on breathing in awake turtles, <italic toggle="yes">Trachemys scripta</italic></article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source><year>2008</year>;<volume>295</volume>:<fpage>R1599</fpage>&#8211;<lpage>1612</lpage>.<pub-id pub-id-type="pmid">18784338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpregu.00020.2008</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeWire</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Yamashita</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Rominger</surname><given-names>DH</given-names></string-name><etal>et al.</etal></person-group><article-title>A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</article-title>. <source>J Pharmacol Exp Ther</source><year>2013</year>;<volume>344</volume>:<fpage>708</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">23300227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.112.201616</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mignat</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wille</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Ziegler</surname><given-names>A.</given-names></string-name></person-group><article-title>Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes</article-title>. <source>Life Sci</source><year>1995</year>;<volume>56</volume>:<fpage>793</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7885194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0024-3205(95)00010-4</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Synthesis, biological, and structural explorations of a series of &#956;-opioid receptor (MOR) agonists with high G protein signaling bias</article-title>. <source>Eur J Med Chem</source><year>2022</year>;<volume>228</volume>:<fpage>113986</fpage>.<pub-id pub-id-type="pmid">34802839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113986</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pradhan</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Kieffer</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>CJ.</given-names></string-name></person-group><article-title>Ligand-directed signalling within the opioid receptor family</article-title>. <source>Br J Pharmacol</source><year>2012</year>;<volume>167</volume>:<fpage>960</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22708627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2012.02075.x</pub-id><pub-id pub-id-type="pmcid">PMC3492979</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grimsrud</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Ivanova</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sherwin</surname><given-names>CM</given-names></string-name><etal>et al.</etal></person-group><article-title>Identification of cytochrome P450 polymorphisms in burn patients and impact on fentanyl pharmacokinetics: a pilot study</article-title>. <source>J Burn Care Res</source><year>2019</year>;<volume>40</volume>:<fpage>91</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30371861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/iry053</pub-id><pub-id pub-id-type="pmcid">PMC6939828</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grimsrud</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Tepper</surname><given-names>CG</given-names></string-name><etal>et al.</etal></person-group><article-title>Pharmacogenetic gene-drug associations in pediatric burn and surgery patients</article-title>. <source>J Burn Care Res</source><year>2022</year>;<volume>43</volume>:<fpage>987</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">35639664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jbcr/irac062</pub-id><pub-id pub-id-type="pmcid">PMC9435482</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saiz-Rodr&#237;guez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ochoa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Herrador</surname><given-names>C</given-names></string-name><etal>et al.</etal></person-group><article-title>Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects</article-title>. <source>Basic Clin Pharmacol Toxicol</source><year>2019</year>;<volume>124</volume>:<fpage>321</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30281924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.13141</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klimas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></string-name></person-group><article-title>Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide</article-title>. <source>Br J Anaesth</source><year>2014</year>;<volume>113</volume>:<fpage>935</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">24985077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aeu186</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ouzzine</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gulberti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ramalanjaona</surname><given-names>N</given-names></string-name><etal>et al.</etal></person-group><article-title>The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication</article-title>. <source>Front Cell Neurosci</source><year>2014</year>;<volume>8</volume>:<fpage>349</fpage>.<pub-id pub-id-type="pmid">25389387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2014.00349</pub-id><pub-id pub-id-type="pmcid">PMC4211562</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gabel</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hovhannisyan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Berkati</surname><given-names>AK</given-names></string-name><etal>et al.</etal></person-group><article-title>Morphine-3-glucuronide, physiology and behavior</article-title>. <source>Front Mol Neurosci</source><year>2022</year>;<volume>15</volume>:<fpage>882443</fpage>.<pub-id pub-id-type="pmid">35645730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2022.882443</pub-id><pub-id pub-id-type="pmcid">PMC9134088</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lotsch</surname><given-names>J.</given-names></string-name></person-group><article-title>Opioid metabolites</article-title>. <source>J Pain Symptom Manage</source><year>2005</year>;<volume>29</volume>:<fpage>10S10</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2005.01.004</pub-id><pub-id pub-id-type="pmid">15907643</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>HS.</given-names></string-name></person-group><article-title>Opioid metabolism</article-title>. <source>Mayo Clin Proc</source><year>2009</year>;<volume>84</volume>:<fpage>613</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">19567715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0025-6196(11)60750-7</pub-id><pub-id pub-id-type="pmcid">PMC2704133</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eshleman</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Nagarajan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wolfrum</surname><given-names>KM</given-names></string-name><etal>et al.</etal></person-group><article-title>Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors</article-title>. <source>Biochem Pharmacol</source><year>2020</year>;<volume>182</volume>:<fpage>114293</fpage>.<pub-id pub-id-type="pmid">33091380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.114293</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>G&#252;nther</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dasgupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Targeting multiple opioid receptors - improved analgesics with reduced side effects?</article-title><source>Br J Pharmacol</source><year>2018</year>;<volume>175</volume>:<fpage>2857</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28378462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13809</pub-id><pub-id pub-id-type="pmcid">PMC6016677</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lefkowitz</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Kobilka</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>MG.</given-names></string-name></person-group><article-title>The new biology of drug receptors</article-title>. <source>Biochem Pharmacol</source><year>1989</year>;<volume>38</volume>:<fpage>2941</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">2551299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(89)90001-4</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Collins</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lefkowitz</surname><given-names>RJ.</given-names></string-name></person-group><article-title>From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors</article-title>. <source>Trends Biochem Sci</source><year>1992</year>;<volume>17</volume>:<fpage>37</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1316650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0968-0004(92)90425-9</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Lefkowitz</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rajagopal</surname><given-names>S.</given-names></string-name></person-group><article-title>Biased signalling: from simple switches to allosteric microprocessors</article-title>. <source>Nat Rev Drug Discov</source><year>2018</year>;<volume>17</volume>:<fpage>243</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">29302067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.229</pub-id><pub-id pub-id-type="pmcid">PMC5936084</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Masoudi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kahsai</surname><given-names>W</given-names></string-name><etal>et al.</etal></person-group><article-title>Mechanism of &#946;(2)AR regulation by an intracellular positive allosteric modulator</article-title>. <source>Science</source><year>2019</year>;<volume>364</volume>:<fpage>1283</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31249059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaw8981</pub-id><pub-id pub-id-type="pmcid">PMC6705129</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shukla</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Manglik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kruse</surname><given-names>AC</given-names></string-name><etal>et al.</etal></person-group><article-title>Structure of active &#946;-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide</article-title>. <source>Nature</source><year>2013</year>;<volume>497</volume>:<fpage>137</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">23604254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12120</pub-id><pub-id pub-id-type="pmcid">PMC3654799</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shukla</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Westfield</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>K</given-names></string-name><etal>et al.</etal></person-group><article-title>Visualization of arrestin recruitment by a G-protein-coupled receptor</article-title>. <source>Nature</source><year>2014</year>;<volume>512</volume>:<fpage>218</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25043026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13430</pub-id><pub-id pub-id-type="pmcid">PMC4134437</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Violin</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Crombie</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name><etal>et al.</etal></person-group><article-title>Biased ligands at G-protein-coupled receptors: promise and progress</article-title>. <source>Trends Pharmacol Sci</source><year>2014</year>;<volume>35</volume>:<fpage>489308</fpage>&#8211;<lpage>316</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2014.04.007</pub-id><pub-id pub-id-type="pmid">24878326</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gurevich</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Gurevich</surname><given-names>EV.</given-names></string-name></person-group><article-title>GPCR signaling regulation: the role of GRKs and arrestins</article-title>. <source>Front Pharmacol</source><year>2019</year>;<volume>10</volume>:<fpage>125</fpage>.<pub-id pub-id-type="pmid">30837883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.00125</pub-id><pub-id pub-id-type="pmcid">PMC6389790</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raehal</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Bohn</surname><given-names>LM.</given-names></string-name></person-group><article-title>Morphine side effects in beta-arrestin 2 knockout mice</article-title>. <source>J Pharmacol Exp Ther</source><year>2005</year>;<volume>314</volume>:<fpage>1195</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">15917400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.105.087254</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bohn</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Lefkowitz</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Gainetdinov</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Peppel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>F-T.</given-names></string-name></person-group><article-title>Enhanced morphine analgesia in mice lacking beta-arrestin 2</article-title>. <source>Science</source><year>1999</year>;<volume>286</volume>:<fpage>2495</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10617462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.286.5449.2495</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Conibear</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Asghar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>R</given-names></string-name><etal>et al.</etal></person-group><article-title>A novel G protein-biased agonist at the &#948; opioid receptor with analgesic efficacy in models of chronic pain</article-title>. <source>J Pharmacol Exp Ther</source><year>2020</year>;<volume>372</volume>:<fpage>224</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">31594792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.119.258640</pub-id><pub-id pub-id-type="pmcid">PMC6978697</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaski</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>JD</given-names></string-name><etal>et al.</etal></person-group><article-title>Potential for kappa-opioid receptor agonists to engineer nonaddictive analgesics: a narrative review</article-title>. <source>Anesth Analg</source><year>2021</year>;<volume>132</volume>:<fpage>406</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">33332902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000005309</pub-id><pub-id pub-id-type="pmcid">PMC7992303</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Nwaneshiudu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Irvine</surname><given-names>K-A</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>JD.</given-names></string-name></person-group><article-title>Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice</article-title>. <source>Anesth Analg</source><year>2019</year>;<volume>129</volume>:<fpage>1414</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">30044299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000003662</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Altarifi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>David</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Muchhala</surname><given-names>KH</given-names></string-name><etal>et al.</etal></person-group><article-title>Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents</article-title>. <source>J Psychopharmacol</source><year>2017</year>;<volume>31</volume>:<fpage>730</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28142305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0269881116689257</pub-id><pub-id pub-id-type="pmcid">PMC5646680</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gillis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gondin</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Kliewer</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group><article-title>Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists</article-title>. <source>Sci Signal</source><year>2020</year>;<volume>13</volume>:<fpage>1</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.aaz3140</pub-id><pub-id pub-id-type="pmid">32234959</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stahl</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Bohn</surname><given-names>LM.</given-names></string-name></person-group><article-title>Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists</article-title>. <source>Biochemistry</source><year>2022</year>;<volume>61</volume>:<fpage>1923</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">34468132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.1c00466</pub-id><pub-id pub-id-type="pmcid">PMC8885792</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gan</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Wase</surname><given-names>L.</given-names></string-name></person-group><article-title>Oliceridine, a G protein-selective ligand at the &#956;-opioid receptor, for the management of moderate to severe acute pain</article-title>. <source>Drugs Today (Barc)</source><year>2020</year>;<volume>56</volume>:<fpage>269</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">32309822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1358/dot.2020.56.4.3107707</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nafziger</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Arscott</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Cochrane</surname><given-names>K</given-names></string-name><etal>et al.</etal></person-group><article-title>The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine</article-title>. <source>Clin Pharmacol Drug Dev</source><year>2020</year>;<volume>9</volume>:<fpage>639</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">31697049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.750</pub-id><pub-id pub-id-type="pmcid">PMC7383509</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Subach</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Sadler</surname><given-names>B</given-names></string-name><etal>et al.</etal></person-group><article-title>First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers</article-title>. <source>J Clin Pharmacol</source><year>2014</year>;<volume>54</volume>:<fpage>351</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24122908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.207</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Subach</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Burnham</surname><given-names>N</given-names></string-name><etal>et al.</etal></person-group><article-title>Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers</article-title>. <source>Pain</source><year>2014</year>;<volume>155</volume>:<fpage>1829</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">24954166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2014.06.011</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Viscusi</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kuss</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group><article-title>A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain</article-title>. <source>Pain</source><year>2016</year>;<volume>157</volume>:<fpage>264</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">26683109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000000363</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singla</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Minkowitz</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name><etal>et al.</etal></person-group><article-title>A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty</article-title>. <source>J Pain Res</source><year>2017</year>;<volume>10</volume>:<fpage>2413</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">29062240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S137952</pub-id><pub-id pub-id-type="pmcid">PMC5638571</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Viscusi</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Skobieranda</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name><etal>et al.</etal></person-group><article-title>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</article-title>. <source>J Pain Res</source><year>2019</year>;<volume>12</volume>:<fpage>927</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">30881102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S171013</pub-id><pub-id pub-id-type="pmcid">PMC6417853</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singla</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Skobieranda</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Soergel</surname><given-names>DG</given-names></string-name><etal>et al.</etal></person-group><article-title>APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty</article-title>. <source>Pain Pract</source><year>2019</year>;<volume>19</volume>:<fpage>715</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">31162798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/papr.12801</pub-id><pub-id pub-id-type="pmcid">PMC6851842</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bergese</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Brzezinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hammer</surname><given-names>GB</given-names></string-name><etal>et al.</etal></person-group><article-title>ATHENA: a Phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the &#181;-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy</article-title>. <source>J Pain Res</source><year>2019</year>;<volume>12</volume>:<fpage>3113</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">31814753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S217563</pub-id><pub-id pub-id-type="pmcid">PMC6861532</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beard</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Michalsky</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Candiotti</surname><given-names>KA</given-names></string-name><etal>et al.</etal></person-group><article-title>Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials</article-title>. <source>Pain Ther</source><year>2020</year>;<volume>10</volume>:<fpage>401</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">33210266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40122-020-00216-x</pub-id><pub-id pub-id-type="pmcid">PMC8119517</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brzezinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hammer</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Candiotti</surname><given-names>KA</given-names></string-name><etal>et al.</etal></person-group><article-title>Low incidence of opioid-induced respiratory depression observed with oliceridine regardless of age or body mass index: exploratory analysis from a phase 3 open-label trial in postsurgical pain</article-title>. <source>Pain Ther</source><year>2021</year>;<volume>10</volume>:<fpage>457</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">33502739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40122-020-00232-x</pub-id><pub-id pub-id-type="pmcid">PMC8119589</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>